FDA Warns Korean Firm for Inadequate Quality Controls, Testing

Drug Industry Daily
A A
The FDA blasted Kolmar Korea for failures to investigate out-of-specification test results and to follow standard operating procedures after a September inspection of its Sejong City facility.

To View This Article:

Login

Subscribe To Drug Industry Daily